Defensin (HBD-2)
Inducible human beta-defensin antimicrobial peptide (41 amino acids) that kills bacteria through membrane disruption at MIC 50 μg/mL against S.
aureus, recruits dendritic cells and T cells via CCR6 receptor chemotaxis, and serves as a critical bridge between innate and adaptive immunity — upregulated up to 100-fold during infection and inflammation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Typical dose
1 µg/mL applied to the wound (e.g. 28 µL of a 1 µg/mL solution, or loaded into a wound dressing)
Compound profile
Scientific & efficacy data
Immune
Peptide profile
Moderate human trials
Defensin (HBD-2)
1 µg/mL applied to the wound (e.g. 28 µL of a 1 µg/mL solution, or loaded into a wound dressing) · As needed
Molecular formula
Approximately C185H290N54O57S6 (41-amino acid peptide with 3 disulfide bonds)
- Mol. weight
- ~4,328 Da (mature peptide)
- CAS number
- Not assigned (endogenous human peptide; research-grade available from multiple suppliers)
- PubChem
- Not assigned (protein/peptide; available via UniProt P60981)
- Developed · 1997 (first isolation from psoriatic skin); subsequent characterization of antimicrobial, chemotactic, and biomarker properties through the 2000s-2020s
- Endogenous; developed by Immuron Limited
Immuron Limited
Amino acid sequence
CIGDPSTENVVQR-CTQQHCSQK-PTLQRPLLHLGerm Fighting
This peptide punches holes in harmful bacteria, yeast, and fungi by attacking their outer walls, working like a natural antibiotic your body makes.
Immune Signaling
It calls in backup by attracting immune cells to infection sites, helping your body's defense team find and fight invaders faster.
Wound Defense
It clears bacteria from wounds while bringing in cells that help repair damaged tissue, supporting healing on two fronts at once.
Dosing
How much do I take?
1 µg/mL applied to the wound (e.g. 28 µL of a 1 µg/mL solution, or loaded into a wound dressing) · per dressing change in the study
1 µg/mL applied to the wound (e.g. 28 µL of a 1 µg/mL solution, or loaded into a wound dressing)
Per dressing change in the study
Covers timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for research into novel topical antimicrobial therapies for skin infections and chronic wounds & biomarker development for inflammatory skin disease monitoring (psoriasis, atopic dermatitis)
Best for
Research into novel topical antimicrobial therapies for skin infections and chronic wounds
Defensin (HBD-2) is particularly well-suited for individuals focused on research into novel topical antimicrobial therapies for skin infections and chronic wounds. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Biomarker development for inflammatory skin disease monitoring (psoriasis, atopic dermatitis)
Defensin (HBD-2) is particularly well-suited for individuals focused on biomarker development for inflammatory skin disease monitoring (psoriasis, atopic dermatitis). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding innate-adaptive immune crossover mechanisms in mucosal defense
Defensin (HBD-2) is particularly well-suited for individuals focused on understanding innate-adaptive immune crossover mechanisms in mucosal defense. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial surfaces and wound dressings incorporating defensin peptides
Defensin (HBD-2) is particularly well-suited for individuals focused on development of antimicrobial surfaces and wound dressings incorporating defensin peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Defensin (HBD-2) with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Topical application (research/wound care) · Aerosolized delivery (pulmonary research)
Route
Defensin (HBD-2) is administered Topical application (research/wound care)—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
3 common side effects · 2 serious
Defensin HBD-2 is not FDA-approved and has no completed human clinical trials, with all safety data limited to in vitro mechanistic studies and animal models.
Animal toxicology studies show no significant systemic toxicity or organ damage at doses exceeding therapeutic levels. However, human immunological responses to exogenously administered antimicrobial peptides are not fully characterized.
Concerns exist regarding potential immune activation, cross-reactivity with self-antigens, and development of antibodies to the synthetic peptide. Bacterial resistance development to defensin-based therapeutics is theoretically possible.
No human pharmacokinetics, dose-escalation studies, Phase 1 safety data, or clinical efficacy trials have been conducted.
Evidence consists of in vitro antimicrobial activity assays against bacteria and fungi, animal infection models showing efficacy, and immunological studies in isolated immune cells. No human safety data, pharmacokinetics, systemic absorption studies, or clinical trials exist.
Published research focuses on mechanism of antimicrobial action and proof-of-concept animal efficacy rather than safety assessment.
Common side effects · experienced by some users
Local site irritation
Mild irritation, redness, or warmth at the site of topical research application, reflecting the peptide's immune cell recruitment and mast cell activation properties.
Management: Expected pharmacological effect from CCR6-mediated chemotaxis. Generally self-limiting. Reduce concentration if irritation is excessive.
Transient inflammatory response
Localized inflammatory response including mild edema and erythema resulting from defensin-mediated immune cell recruitment and mast cell degranulation.
Management: Monitor and document. Expected in research settings. The inflammatory response is part of the peptide's mechanism of bridging innate and adaptive immunity.
Reduced activity in saline environments
Not a side effect per se, but clinically relevant: HBD-2 antimicrobial activity is significantly reduced at physiological NaCl concentrations (>150 mM), limiting efficacy in some clinical scenarios.
Management: Use low-ionic-strength formulation buffers. Consider combining with salt-insensitive peptides (HBD-3, LL-37) for applications requiring activity in physiological conditions.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Defensin (HBD-2)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Defensin (HBD-2) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:HBD-3 (Human Beta-Defensin 3) — complementary defensin with salt-insensitive activity that compensates for HBD-2's salt sensitivity in physiological environments — May be used together under medical guidance.
- Safe:LL-37 (Cathelicidin) — synergistic antimicrobial activity through complementary membrane disruption mechanisms; LL-37 provides salt-resistant killing — May be used together under medical guidance.
- Safe:Lysozyme — natural antimicrobial enzyme that synergizes with defensins by cleaving peptidoglycan while defensins disrupt outer membrane integrity — May be used together under medical guidance.
With medications
- Caution:High-concentration NaCl solutions — salt concentrations above 150 mM significantly reduce HBD-2 antimicrobial activity through electrostatic charge shielding — Use with caution—discuss with your healthcare provider.
- Caution:Anionic polymers or surfactants — may complex with cationic HBD-2 and neutralize antimicrobial activity — Use with caution—discuss with your healthcare provider.
- Caution:Immunosuppressive agents in research settings — may counteract the immunomodulatory chemotactic effects of HBD-2 — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Defensin (HBD-2). Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Moderate human trials · first signs minutes to hours (acute phase)
Evidence level
Moderate human trials
(Phase 1-2)
Regulatory status
Research compound
Onset of effects
Rapid
(hours to days)
How it works
Human beta-defensin-2 (HBD-2) is an antimicrobial peptide your skin and immune cells produce to fight bacteria, fungi, and viruses while also modulating inflammation and promoting wound healing.
The deeper mechanism
HBD-2 is a 4-kDa cationic antimicrobial peptide containing three disulfide bonds formed between conserved cysteine residues, creating a rigid β-sheet structure.
Its cationic amino acids interact electrostatically with anionic bacterial and fungal membranes, causing membrane perturbation and microbicidal activity.
Beyond direct antimicrobial effects, HBD-2 functions as an immunomodulator through CC chemokine receptor signaling (particularly CCR2 and CCR6), recruiting immune cells to sites of infection and inflammation, and suppressing excessive pro-inflammatory responses through TLR4 pathway modulation.
What to expect
Minutes to hours (acute phase)
What you might notice
- Immediate antimicrobial activity against susceptible organisms upon contact
- Rapid bacterial membrane disruption and pathogen killing in low-salt conditions
- Mild local redness or warmth from initial immune cell recruitment
- Mast cell activation at the application site
What's normal
- HBD-2 acts rapidly — antimicrobial killing begins within minutes of contact
- Local inflammatory response reflects CCR6-mediated chemotaxis of immune cells
- This is a research compound — effects are observed in experimental settings
What's next
- Monitor antimicrobial efficacy through bacterial culture or viability assays
- Assess immune cell recruitment through histological or flow cytometry analysis
- Continue application per research protocol
Days 1-7 (research protocol)
What you might notice
- Reduction in bacterial colonization at treated sites
- Enhanced immune cell infiltration (dendritic cells, T cells) at application area
- Improved wound bed appearance in wound infection models
- Potential synergistic effects if combined with other antimicrobial peptides
What's normal
- Continued antimicrobial effect with daily application
- Adaptive immune activation becomes measurable as recruited dendritic cells process antigens
- Salt sensitivity may limit efficacy in high-NaCl environments — adjust formulation if needed
What's next
- Assess treatment endpoints defined in research protocol
- Consider combination approaches with salt-insensitive peptides if activity is suboptimal
- Document immune cell populations and bacterial burden at study endpoints
Week 2-4 (extended research protocol)
What you might notice
- Significant reduction or clearance of target pathogens
- Measurable adaptive immune responses from CCR6-mediated dendritic cell activation
- Tissue remodeling and healing in wound infection models
- Biomarker changes reflecting reduced infection and inflammation
What's normal
- Extended application provides sustained antimicrobial pressure
- The bridge to adaptive immunity becomes functionally apparent over this timeframe
- Wound models show healing progression combining antimicrobial and immunomodulatory effects
What's next
- Complete research protocol endpoints and data collection
- Analyze innate-to-adaptive immune transition markers
- Report findings for potential clinical translation
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Defensin (HBD-2) over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
What is Human Beta-Defensin 2 and how was it discovered?
HBD-2 is a 41-amino acid cationic antimicrobial peptide that was first isolated from psoriatic skin lesions by Jürgen Harder and colleagues at the University of Kiel, Germany in 1997. It is encoded by the DEFB4A gene on chromosome 8p23.1 and belongs to the beta-defensin family, characterized by six conserved cysteine residues that form three intramolecular disulfide bonds. HBD-2 was the first inducible human beta-defensin identified and is now recognized as a cornerstone of epithelial innate immunity.
How does HBD-2 bridge innate and adaptive immunity?
HBD-2 has a unique dual function: it directly kills pathogens through membrane disruption (innate immunity) while simultaneously binding the CC chemokine receptor 6 (CCR6) on immature dendritic cells, memory T cells, and mast cells, recruiting them to infection sites (adaptive immune activation). This means HBD-2 not only eliminates pathogens immediately but also orchestrates the longer-term adaptive immune response by bringing antigen-presenting dendritic cells to encounter pathogens — a capability rare among antimicrobial peptides.
Why is HBD-2 salt-sensitive and what does this mean?
HBD-2's antimicrobial activity depends on electrostatic attraction between the cationic peptide and anionic bacterial membranes. At NaCl concentrations above 150 mM, salt ions shield these charges, reducing the peptide's ability to bind and disrupt bacterial membranes. This is clinically relevant because cystic fibrosis patients have elevated airway salt concentrations, which may explain their increased susceptibility to lung infections — their endogenous defensins are inhibited by the abnormal salt environment.
How does HBD-2 relate to psoriasis?
HBD-2 was originally discovered in psoriatic skin lesions where its expression is dramatically upregulated. Serum HBD-2 levels correlate with the Psoriasis Area and Severity Index (PASI), making it a useful biomarker for disease activity monitoring. While elevated HBD-2 contributes to the antimicrobial defense of psoriatic skin (explaining why psoriasis patients rarely get skin infections), the persistent overexpression may also contribute to chronic immune cell recruitment through CCR6, potentially perpetuating the inflammatory cycle.
How does HBD-2 compare to HBD-3?
While both are beta-defensins with antimicrobial and immunomodulatory functions, they differ in key ways. HBD-2 is salt-sensitive (reduced activity at >150 mM NaCl) while HBD-3 retains full activity in physiological salt conditions. HBD-3 is considerably more potent — its MIC against MRSA is 0.5-1.0 μg/mL compared to HBD-2's 50 μg/mL against S. aureus. However, HBD-2 has stronger CCR6-mediated chemotactic activity for dendritic cells. They are complementary in epithelial defense, with HBD-2 providing immune cell recruitment and HBD-3 providing potent, salt-resistant killing.
What is the potential for HBD-2 as a therapeutic?
HBD-2 is being investigated for several therapeutic applications: topical wound care (combining antimicrobial and healing properties), antimicrobial coatings for medical devices, aerosolized pulmonary delivery for respiratory infections, and as a biomarker for inflammatory diseases. Challenges include salt sensitivity limiting activity in some environments, production costs for disulfide-bonded peptides, and the need for clinical trials to establish safety and efficacy. Strategies to overcome salt sensitivity include combining with HBD-3 or engineering salt-resistant defensin variants.
Further reading
History & related research
History · since 1997
The Skin's Secret Antibiotic Hidden in Plain Sight
When dermatologists noticed that psoriasis patients almost never got skin infections — despite having raw, inflamed skin — they went looking for answers. What they found was a tiny natural antibiotic produced by skin cells themselves, rewriting everything we knew about how skin protects us.
Read the full history of Defensin (HBD-2)Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Defensin (HBD-2), on one page.